CPH Cipher Pharmaceuticals Inc.
13.70CAD+0.37%Mkt Cap: 253.57M $P/E: 8.951d ago
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and r…
Industry Peers
Drug Manufacturers - Specialty & Generic$64.30BUSDP/E 25.0
$56.90BUSD
$46.26BUSDP/E 66.1
$38.79BUSDP/E 18.0
$29.51BUSDP/E 11.7
$28.27BUSDP/E 12.1
$23.01BUSDP/E 19.2
$20.24BUSD
$14.14BUSDP/E 110.6
$14.66BUSDP/E 21.1
$12.60BUSDP/E 22.8
$11.25BUSD
$10.26BUSDP/E 28.0
$8.59BUSDP/E 19.2
$7.17BUSDP/E 112.5
$7.09BUSDP/E 41.5
$6.92BUSD
$6.54BUSDP/E 24.3
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.$5.17BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Cipher Pharmaceuticals Inc (CPHRF) (Q2 2026) Earnings Call Highlights: Epuris Growth and ... Despite a 10% revenue dip from Medicaid-related Natroba declines, Cipher boosts Epuris market share to 47.1% and secures a major Walmart retail partnership. | ||
 Cipher Pharmaceuticals Q2 Earnings Call Highlights Cipher Pharmaceuticals (TSE:CPH) reported lower second-quarter revenue and earnings as sales of its U.S. Natroba treatment declined, while its Canadian Epuris product posted growth and market-share gains. Management said the company remains focused on expanding commercial channels for Natroba, widen | ||